

SWISS HELVETIA FUND, INC.

Form N-Q

November 28, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM N-Q**

**QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS**

**OF REGISTERED MANAGEMENT INVESTMENT COMPANY**

**Investment Company Act file number: 811-05128**

**The Swiss Helvetia Fund, Inc.**

**875 Third Avenue, 22<sup>nd</sup> Floor**

**New York, NY 10022**

**Mark Hemenetz**

**Schroder Investment Management North America Inc.**

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

**875 Third Avenue, 22<sup>nd</sup> Floor**

**New York, NY 10022**

**Registrant's telephone number, including area code: 1-800-730-2932**

**Date of fiscal year end: December 31**

**Date of reporting period: September 30, 2014**

**Item 1. Schedule of Investments.**

## THE SWISS HELVETIA FUND, INC.

## Schedule of Investments by Industry (Unaudited)

September 30, 2014

No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stocks 85.70%</b>			
<b>Banks 5.37%</b>			
264,600	<b>Credit Suisse Group AG</b> A global diversified financial services company with significant activity in private banking, investment banking and asset management. (Cost \$6,313,425)	\$ 7,330,154	1.78%
430,000	<b>EFG International AG</b> A global private banking group offering private banking and asset management services. (Cost \$4,946,621)	4,324,751	1.05%
600,500	<b>UBS AG</b> A global diversified financial service company with significant activity in private banking, investment banking, and asset management. (Cost \$7,876,986)	10,470,257	2.54%
		22,125,162	5.37%
<b>Biotechnology 7.77%</b>			
116,000	<b>Actelion, Ltd.<sup>1</sup></b> Focuses on the discovery, development and commercialization of treatments to serve critical, unmet medical needs. (Cost \$6,632,516)	13,633,491	3.32%
60,000	<b>Basilea Pharmaceutica AG<sup>2</sup></b> Conducts research into the development of drugs for the treatment of infectious diseases and dermatological problems. (Cost \$4,710,888)	6,021,978	1.46%
1,600,000	<b>Evolva Holding SA<sup>2</sup></b> Discovers and provides innovative, sustainable ingredients for health, nutrition and wellness. (Cost \$1,272,422)	2,076,400	0.50%
85,000	<b>Lonza Group AG</b> Produces organic fine chemicals, biocides, active ingredients, and biotechnology products. Operates production sites in Europe, the United States, and China. (Cost \$8,018,017)	10,265,829	2.49%
		31,997,698	7.77%
No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Chemicals 3.21%</b>			
140,000	<b>Clariant AG</b> Develops, produces, markets and sells specialty chemical products for various end markets. (Cost \$2,450,385)	\$ 2,397,070	0.58%
34,000	<b>Syngenta AG</b> Produces herbicides, insecticides and fungicides, and seeds for field crops, vegetables, and flowers. (Cost \$11,412,216)	10,828,048	2.63%

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

		13,225,118	3.21%
<b>Construction &amp; Materials 3.23%</b>			
<b>3,150</b>	<b>Belimo Holding AG</b> World market leader in damper and volume control actuators for ventilation and air-conditioning equipment. (Cost \$6,598,993)	7,846,154	1.90%
<b>100,000</b>	<b>Implenia AG</b> Provides construction, civil and underground engineering services. Implenia's projects include residential and industrial buildings, tunnels, bridges and roads. The company also provides real estate and facilities management and marketing services. (Cost \$6,306,426)	5,463,108	1.33%
		13,309,262	3.23%
<b>Financial Services 1.74%</b>			
<b>28,000</b>	<b>Leonteq AG</b> Is a technology and service platform with a leading position in structured investment products in Switzerland. (Cost \$5,302,668)	6,250,549	1.51%
<b>5,500</b>	<b>VZ Holding AG</b> Provides independent financial advice to private individuals and companies. The company consults on investment, tax and inheritance planning and provides advice regarding insurance products and coverage. (Cost \$931,588)	930,194	0.23%
		7,180,743	1.74%

See Notes to Schedule of Investments.

## THE SWISS HELVETIA FUND, INC.

## Schedule of Investments by Industry (Unaudited)

September 30, 2014

(continued)

No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stocks (continued)</b>			
<b>Food &amp; Beverage 13.35%</b>			
320	<b>Lindt &amp; Sprungli AG<sup>1</sup></b> Major manufacturer of premium Swiss chocolates. (Cost \$9,265,642)	\$ 18,983,987	4.61%
490,000	<b>Nestle SA<sup>1</sup></b> Largest food and beverage processing company in the world. (Cost \$6,459,887)	36,025,641	8.74%
		55,009,628	13.35%
<b>Industrial Goods &amp; Services 10.24%</b>			
100,000	<b>Adecco SA</b> Supplies personnel and temporary help, and offers permanent placement services internationally for professionals and specialists in a range of occupations. (Cost \$8,405,776)	6,787,023	1.65%
42,200	<b>Bucher Industries AG<sup>1</sup></b> Manufactures food processing machinery, vehicles, and hydraulic components. Produces fruit and vegetable juice processing machinery, farming machinery and outdoor equipment. (Cost \$12,678,466)	10,855,845	2.64%
34,000	<b>Burckhardt Compression Holding AG<sup>1</sup></b> Produces compressors for oil refining and the chemical and petrochemical industries, industrial gases, and gas transport and storage. (Cost \$11,079,229)	15,710,099	3.81%
105,000	<b>DKSH Holding, Ltd.</b> An international marketing and services group. The company offers a comprehensive package of services that includes organizing and running the entire value chain for any product. (Cost \$8,104,918)	7,829,670	1.90%
8,000	<b>Panalpina Welttransport Holding AG</b> One of the largest transporters of freight by air and ship, and offers warehousing and distribution services. (Cost \$826,833)	1,005,547	0.24%
		42,188,184	10.24%
No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Insurance 2.67%</b>			
126,200	<b>Schweizerische National-Versicherungs-Gesellschaft AG<sup>1</sup></b> Offers insurance products in Europe, including reinsurance, health, transport, legal, technical, accident, travel, automobile, fire and theft insurance. (Cost \$8,646,941)	\$ 11,015,259	2.67%
		11,015,259	2.67%

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

**Medical Equipment 5.98%**

<b>168,000</b>	<b>Kuros Biosurgery AG<sup>2,3</sup></b> Develops biomaterials and bioactive biomaterial combination products for trauma, wound and spine indications. (Cost \$2,516,639)	703,297	0.17%
<b>90,000</b>	<b>Sonova Holding AG<sup>1</sup></b> Designs and produces wireless analog and digital in-the-ear and behind-the-ear hearing aids and miniaturized voice communications systems. (Cost \$13,808,224)	14,373,626	3.50%
<b>3,731</b>	<b>Spineart SA<sup>2,3</sup></b> Designs and markets an innovative full range of spine products, including fusion and motion preservation devices, focusing on easy to implant high-end products to simplify the surgical act. (Cost \$2,623,329)	1,861,166	0.45%
<b>73,000</b>	<b>Tecan Group AG</b> Manufactures and distributes laboratory automation components and systems. The products are mainly used by research and diagnostic laboratories. (Cost \$7,277,876)	7,678,179	1.86%
		24,616,268	5.98%

**Personal & Household Goods 3.96%**

<b>92,000</b>	<b>Compagnie Financiere Richemont SA</b> Manufactures and retails luxury goods. Produces jewelry, watches, leather goods, writing instruments, and men's and women's wear. (Cost \$6,423,112)	7,543,904	1.83%
---------------	---	-----------	-------

*See Notes to Schedule of Investments.*

## THE SWISS HELVETIA FUND, INC.

## Schedule of Investments by Industry (Unaudited)

September 30, 2014

(continued)

No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stocks (continued)</b>			
<b>Personal &amp; Household Goods (continued)</b>			
<b>100,000</b>	<b>Swatch Group AG</b> Manufactures finished watches, movements and components. Produces components necessary to its eighteen watch brand companies. Also operates retail boutiques.  (Cost \$9,713,969)	\$ 8,749,346	2.13%
		16,293,250	3.96%
<b>Pharmaceuticals 25.49%</b>			
<b>530,000</b>	<b>Novartis AG<sup>1</sup></b> One of the leading manufacturers of branded and generic pharmaceutical products.  (Cost \$10,426,546)	50,004,710	12.14%
<b>3,029</b>	<b>NovImmune SA<sup>2,3</sup></b> Discovers and develops therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.  (Cost \$1,551,109)	2,149,306	0.52%
<b>178,500</b>	<b>Roche Holding AG<sup>1</sup></b> Develops and manufactures pharmaceutical and diagnostic products. Produces prescription drugs to treat cardiovascular, infectious, autoimmune, and for other areas including dermatology and oncology.  (Cost \$13,275,119)	52,886,812	12.83%
		105,040,828	25.49%
<b>Retail 1.13%</b>			
<b>30,500</b>	<b>Dufry AG<sup>2</sup></b> Operates duty-free shops in countries such as the Caribbean, France, Italy, Mexico, Russia, Singapore, the United Arab Emirates and the United States.  (Cost \$5,588,176)	4,647,619	1.13%
		4,647,619	1.13%
No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Technology 1.56%</b>			
<b>500,000</b>	<b>Logitech International SA<sup>2</sup></b> Engages in the development and marketing of hardware and software products that enable or enhance digital navigation, music and video entertainment, gaming, social networking, and audio and video communication.	\$ 6,436,421	1.56%



Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

(Cost \$6,778,232)

		6,436,421	1.56%
<b>Total Common Stocks</b>			
	(Cost \$218,223,174)	353,085,440	85.70%
<b>Preferred Stocks 1.13%</b>			
<b>Biotechnology 0.29%</b>			
<b>8,400</b>	<b>Ixodes AG, Series B<sup>3,5</sup></b>	1,202,462	0.29%
	Develops and produces a topical product for the treatment of borreliosis infection and the prevention of Lyme disease after a tick bite.		
	(Cost \$2,252,142)		
		1,202,462	0.29%
<b>Industrial Goods &amp; Services 0.13%</b>			
<b>250,447</b>	<b>SelFrag AG, Class A, Series C<sup>3,5</sup></b>	275,217	0.06%
<b>78,514</b>	<b>SelFrag AG, Class A, Series D<sup>3,5</sup></b>	86,279	0.02%
<b>171,902</b>	<b>SelFrag AG, Class A, Series E<sup>3,5</sup></b>	188,903	0.05%
	Designs, manufactures and sells industrial machines and processes using selective fragmentation technology.		
	(Cost \$1,932,198)		
		550,399	0.13%
<b>Medical Equipment 0.16%</b>			
<b>83,611</b>	<b>EyeSense AG, Series C<sup>3,5</sup></b>	638,786	0.16%
	A spin-out from Ciba Vision AG. Develops novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients. (Cost \$3,007,048)		
		638,786	0.16%

See Notes to Schedule of Investments.

## THE SWISS HELVETIA FUND, INC.

## Schedule of Investments by Industry (Unaudited)

September 30, 2014

(continued)

No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Preferred Stocks (continued)</b>			
<b>Pharmaceuticals 0.55%</b>			
3,162	<b>NovImmune SA, Series B<sup>3</sup></b> Discovers and develops therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.  (Cost \$2,062,307)	\$ 2,243,679	0.55%
		<u>2,243,679</u>	<u>0.55%</u>
	<b>Total Preferred Stocks</b>  (Cost \$9,253,695)	4,635,326	1.13%
<b>Private Equity Limited Partnerships 4.18%</b>			
<b>Biotechnology 0.69%</b>			
	<b>Aravis Biotech II - Limited Partnership<sup>2,3,5</sup></b> (Cost \$2,750,654)	2,836,870	0.69%
<b>Financial Services 3.49%</b>			
	<b>Zurmont Madison Private Equity, Limited Partnership<sup>1,2,3,5</sup></b> (Cost \$13,671,329)	14,374,878	3.49%
	<b>Total Private Equity Limited Partnerships</b>  (Cost \$16,421,983)	17,211,748	4.18%
	<b>Total Investments*</b>  (Cost \$243,898,852)	374,932,514	91.01%
	<b>Other Assets Less Other Liabilities, net</b>	<u>37,014,699</u>	<u>8.99%</u>
	<b>Net Assets</b>	<u>\$ 411,947,213</u>	<u>100.00%</u>

See Notes to Schedule of Investments.

## THE SWISS HELVETIA FUND, INC.

## Schedule of Investments (Unaudited) (continued)

September 30, 2014

<sup>1</sup> One of the ten largest portfolio holdings.<sup>2</sup> Non-income producing security.<sup>3</sup> Illiquid. There is not a public market for these securities in the United States or in any foreign jurisdiction, including Switzerland. Securities are priced at Fair Value in accordance with the Fund's valuation policy and procedures. At the end of the period, the aggregate Fair Value of these securities amounted to \$26,560,843 or 6.45% of the Fund's net assets. Additional information on these securities is as follows:

Security	Acquisition Date	Acquisition Cost
Aravis Biotech II, Limited Partnership	July 31, 2007 - November 25, 2013	\$ 2,750,654
EyeSense AG Preferred Shares C	July 22, 2010 - October 3, 2011	3,007,048
Ixodes AG Preferred Shares B	April 7, 2011 - June 1, 2012	2,252,142
Kuros Biosurgery AG Common Shares	August 10, 2009 - August 28, 2009	2,516,639
NovImmune SA Common Shares	October 7, 2009 - December 11, 2009	1,551,109
NovImmune SA Preferred Shares B	October 7, 2009 - December 11, 2009	2,062,307
SelFrag AG - Class A Preferred Shares	December 15, 2011 - January 28, 2014	1,932,198
Spineart SA Common Shares	December 22, 2010	2,623,329
Zurmont Madison Private Equity, Limited Partnership	September 13, 2007 - July 18, 2014	13,671,329
		<u>\$ 32,366,755</u>

<sup>4</sup> The Fund has a fundamental investment policy that prohibits it from investing 25% or more of its total assets in a particular industry. As of September 30, 2014, the Fund had more than 25% of its total assets invested in the pharmaceuticals industry as a result of the appreciation of the value of its existing investments. The Fund will not invest in any additional companies in the industry until such time that the percentage of the Fund's total assets invested in that industry is below 25%.<sup>5</sup> Affiliated Company. An affiliated company is a company in which the Fund has ownership of at least 5% of the company's outstanding voting securities or an equivalent interest in the company. Details related to affiliated company holdings are as follows:

Name of Issuer	Fair Value as of 12/31/13	Gross Additions	Gross Reductions	Fair Value as of 9/30/14
Aravis Biotech II, Limited Partnership	\$ 3,084,787	\$	\$	\$ 2,836,870
EyeSense AG Preferred Shares C	1,411,990			638,786
Ixodes AG Preferred Shares B	1,291,901			1,202,462
SelFrag AG - Class A Preferred Shares	935,650	94,134		550,399
Zurmont Madison Private Equity, Limited Partnership	15,067,184	313,480		14,374,878
Total	<u>\$ 21,791,512</u>	<u>\$ 407,614</u>	<u>\$</u>	<u>\$ 19,603,395</u>

\* Cost for Federal income tax purposes is \$242,606,529 and net unrealized appreciation (depreciation) consists of:

Gross Unrealized Appreciation	\$ 149,154,232
Gross Unrealized Depreciation	(16,828,247)
Net Unrealized Appreciation (Depreciation)	<u>\$ 132,325,985</u>

See Notes to Schedule of Investments.



## THE SWISS HELVETIA FUND, INC.

## Schedule of Investments by Industry (Unaudited) (concluded)

September 30, 2014

**PORTFOLIO HOLDINGS****% of Net Assets as of September 30, 2014**

Common Stocks	
Pharmaceuticals	25.49%
Food & Beverage	13.35%
Industrial Goods & Services	10.24%
Biotechnology	7.77%
Medical Equipment	5.98%
Banks	5.37%
Personal & Household Goods	3.96%
Construction & Materials	3.23%
Chemicals	3.21%
Insurance	2.67%
Financial Services	1.74%
Technology	1.56%
Retail	1.13%
Preferred Stocks	
Pharmaceuticals	0.55%
Biotechnology	0.29%
Medical Equipment	0.16%
Industrial Goods & Services	0.13%
Private Equity Limited Partnerships	4.18%
Other Assets Less Other Liabilities, net	8.99%
	100.00%

See Notes to Schedule of Investments.

---

THE SWISS HELVETIA FUND, INC.

---

Notes to Schedule of Investments (Unaudited)

**Note 1 Organization and Significant Accounting Policies**

**A. Organization**

The Swiss Helvetia Fund, Inc. (the Fund) is registered under the Investment Company Act of 1940, as amended (the Act), as a non-diversified, closed-end management investment company. The Fund is organized as a corporation under the laws of the State of Delaware.

The investment objective of the Fund is to seek long-term growth of capital through investment in equity and equity-linked securities of Swiss companies. The Fund may also acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances.

**B. Securities Valuation**

The Fund values its investments at fair value in accordance with accounting principles generally accepted in the United States (GAAP).

When valuing listed equity securities, the Fund uses the last sale price on the securities exchange or national securities market on which such securities primarily are traded (the Primary Market) prior to the calculation of the Fund's net asset value (NAV). When valuing equity securities that are not listed (except privately-held companies and private equity limited partnerships) or that are listed but have not traded on a day on which the Fund calculates its NAV, the Fund uses the mean between the bid and asked prices for that day. If there are no asked quotations for such a security, the value of such security will be the most recent bid quotation on the Primary Market on that day. On any day when a security's Primary Market is closed because of a local holiday or other scheduled closure, but the New York Stock Exchange is open, the Fund may use the prior day's closing prices to value such security regardless of the length of the scheduled closing.

When valuing fixed-income securities, the Fund uses the last bid price prior to the calculation of the Fund's NAV. If there is no current bid price for a fixed-income security, the value of such security will be the mean between the last quoted bid and asked prices on that day. Overnight and certain other short-term fixed-income securities with maturities of less than sixty days will be valued by the amortized cost method, unless it is determined that the amortized cost method would not represent the fair value of such security.

It is the responsibility of the Fund's Board of Directors (the Board) to establish procedures to provide for the valuation of the Fund's portfolio holdings. When valuing securities for which market quotations are not readily available, or for which the market quotations that are available are considered unreliable, the Fund determines a fair value in good faith in accordance with these procedures (a Fair Value). The Fund may use these procedures to establish the Fair Value of securities when, for example, a significant event occurs between the time the market closes and the time the Fund values its investments. After consideration of various factors, the Fund may value the securities at their last reported price or at some other value.

## Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

Swiss exchange-listed options, including Eurex-listed options, are valued at their most recent sale price (latest bid for long options and the latest ask for short options) on the Primary Market, or if there are no such sales, at the average of the most recent bid and asked quotations on such Primary Market, or if such quotations are not available, at the last bid quotation (in the case of purchased options) or the last asked quotation (in the case of written options). If, however, there are no such quotations, such options will be valued using the implied volatilities observed for similar options or from aggregated data as an input to a model. Options traded in the over-the-counter market are valued at the price communicated by the counterparty to the option, which typically is the price at which the counterparty would close out the transaction. Option contracts that are neither exchange-listed nor traded in the over-the-counter market, and where no broker can provide a quote or approved pricing vendor a price, may be valued using the implied volatilities observed for similar instruments or from aggregated market data received from services (e.g., Bloomberg) as an input to a widely-accepted model.

---

 THE SWISS HELVETIA FUND, INC.
 

---

## Notes to Schedule of Investments (Unaudited) (continued)

The Fund is permitted to invest in investments that do not have readily available market quotations. For such investments, the Act requires the Board to determine their Fair Value. The aggregate value of these investments amounted to \$26,560,843, or 6.45% of the Fund's net assets at September 30, 2014, and are listed in Note 3 to the Schedule of Investments.

Various inputs are used to determine the value of the Fund's investments. These inputs are summarized in the three broad levels listed below:

Level 1 unadjusted quoted prices in active markets for identical assets and liabilities

Level 2 other significant observable inputs (including quoted prices of similar securities, interest rates, prepayment speeds, credit risk, etc.)

Level 3 significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments)

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of September 30, 2014:

	Level 1 Quoted Prices	Level 2 Other Significant Observable Inputs	Level 3 Significant Unobservable Inputs	Total
	<u>                    </u>	<u>                    </u>	<u>                    </u>	<u>                    </u>
<b>Investments in Securities</b>				
Common Stock*	\$ 348,371,671	\$	\$ 4,713,769	\$ 353,085,440
Preferred Stock*			4,635,326	4,635,326
Private Equity Limited Partnerships			17,211,748	17,211,748
	<u>                    </u>	<u>                    </u>	<u>                    </u>	<u>                    </u>
<b>Total Investments in Securities</b>	<b>\$ 348,371,671</b>	<b>\$</b>	<b>\$ 26,560,843</b>	<b>\$ 374,932,514</b>
	<u>                    </u>	<u>                    </u>	<u>                    </u>	<u>                    </u>

\* Please see the Schedule of Investments for industry classifications.

Level 3 securities, which are listed in Note 3 to the Schedule of Investments, consist of the Fund's investments in privately-held companies and private equity limited partnerships that invest in privately-held companies.



## Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

Inputs and valuation techniques used by the Fund to value its Level 3 investments in privately-held companies may include the following: acquisition cost; fundamental analytical data; discounted cash flow analysis; nature and duration of restrictions on disposition of the investment; public trading of similar securities of similar issuers; economic outlook and condition of the industry in which the issuer participates; financial condition of the issuer; and the issuer's prospects, including any recent or potential management or capital structure changes. At September 30, 2014, the common shares and preferred shares, series B of NovImmune SA, a privately-held company, were valued based on a market approach using the most recent observable round of financing. Although these valuation inputs may be observable in the marketplace as is characteristic of Level 2 investments, the privately-held companies, categorized as Level 3 investments, generally are highly illiquid in terms of resale.

The Fund values its Level 3 investments in the two private equity limited partnerships in accordance with Accounting Standards Codification 820-10-35, *Investments in Certain Entities that Calculate Net Asset Value Per Share (Or its Equivalent)* (ASC 820-10-35). ASC 820-10-35 permits a reporting entity to measure the fair value of an investment that does not have a readily determinable fair value, based on the NAV of the investment as a practical expedient, without further adjustment, unless it is probable that the investment will be sold at a value significantly different than the NAV. If the NAV of the investment is not as of the Fund's measurement date, then the NAV should be adjusted to reflect any significant events that may change the valuation. Inputs and valuation techniques for these adjustments may include fair valuations of the partnerships and their portfolio holdings provided by the partnerships' general partners or managers, other available information about the partnerships' portfolio holdings, values obtained on redemption from other limited partners, discussions with the partnerships' general partners or managers and/or other limited partners and comparisons of previously-obtained estimates to the partnerships' audited financial statements. In using the unadjusted NAV as a practical expedient, certain attributes of the investment that may impact its fair value are not considered. Attributes of those investments include the investment strategies of the privately-held companies and may also include, but are not limited to, restrictions on the investor's ability to redeem its investments at the measurement date and any unfunded commitments.

## THE SWISS HELVETIA FUND, INC.

## Notes to Schedule of Investments (Unaudited) (continued)

When valuing Level 3 investments, management also may consider potential events that could have a material impact on the operations of a privately-held company or private equity limited partnership. Not all of these factors may be considered or available, and other relevant factors may be considered on an investment-by-investment basis. The table below summarizes the techniques and unobservable inputs for the valuation of Level 3 investments.

## Quantitative Information about certain Level 3 Fair Value Measurements

	Fair Value at September 30, 2014	Valuation Technique	Unobservable inputs	Range <sup>1</sup>
Privately-held companies Medical Equipment <sup>2</sup>	\$3,203,249	Discounted cash flow	Weighted average cost of capital Expected compound annual growth rate of revenue (10 years)	12.4%-17% 27%-47%
Privately-held companies Pharmaceuticals <sup>3</sup>	\$4,392,985	Market approach	Recent round of financing	N/A
Privately-held companies Biotechnology <sup>4</sup>	\$1,202,462	Discounted cash flow	Weighted average cost of capital Success rate on research and development	16% 40%
Privately-held companies Industrial Goods & Services <sup>5</sup>	\$550,399	Discounted cash flow	Weighted average cost of capital Expected compound annual growth rate of revenue (5 years)	14% 37%
Private Equity Limited Partnerships Biotechnology	\$2,836,870	NAV as a practical expedient	N/A	N/A
Private Equity Limited Partnerships Financial Services	\$14,374,878	NAV as a practical expedient	N/A	N/A
Total	\$26,560,843			

<sup>1</sup> Significant changes in any of these ranges would result in a significantly higher or lower fair value measurement. Generally, a change in the success rate on research and development or the expected long-term 10-year revenue growth rate is accompanied by a directionally similar change in fair value. Conversely, a change in the weighted average cost of capital is accompanied by a directionally opposite change in fair value.

<sup>2</sup> Eyesense AG Preferred Shares, Kuros Biosurgery AG Common Shares, Spineart SA Common Shares were valued based on this technique.

<sup>3</sup> Novimmune SA Common Shares and Preferred Shares were valued based on this technique.

<sup>4</sup> Ixodes Preferred Shares were valued based on this technique

<sup>5</sup> SelFrag AG Preferred Shares were valued based on this technique.

The Fund's policy is to disclose transfers between Levels based on their market prices at the reporting period end. There were no transfers between Levels for the three-month period ended September 30, 2014.

The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value.

	Common	Preferred	Private Equity Limited	Total
--	--------	-----------	---------------------------	-------

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

	Stock	Stock	Partnerships	_____
Balance as of December 31, 2013	\$ 5,064,380	\$ 6,050,106	\$ 18,151,971	\$ 29,266,457
Change in Unrealized Appreciation/Depreciation*	(350,611)	(1,508,914)	(1,253,703)	(3,113,228)
Net Realized Gain (Loss)				
Gross Purchases		94,134	313,480	407,614
Gross Sales				
Balance as of September 30, 2014	\$ 4,713,769	\$ 4,635,326	\$ 17,211,748	\$ 26,560,843

\* The noted amounts of change in unrealized appreciation/depreciation relate to the fair value of Level 3 assets held on September 30, 2014.

---

THE SWISS HELVETIA FUND, INC.

---

Notes to Schedule of Investments (Unaudited) (concluded)

**C. Foreign Currency Translation**

The Fund maintains its accounting records in U.S. dollars. The Fund's assets are invested primarily in Swiss equities. In addition, the Fund can make its temporary investments in Swiss franc-denominated bank deposits, short-term debt securities and money market instruments. Substantially all income received by the Fund is in Swiss francs. The Fund's NAV, however, is reported, and distributions from the Fund are made, in U.S. dollars, resulting in gain or loss from currency conversions in the ordinary course of business. Historically, the Fund has not entered into transactions designed to reduce currency risk and does not intend to do so in the future. The cost basis of foreign denominated assets and liabilities is determined on the date that they are first recorded within the Fund and translated to U.S. dollars. These assets and liabilities are subsequently valued each day at prevailing exchange rates. The difference between the original cost and current value denominated in U.S. dollars is recorded as unrealized foreign currency gain/loss. In valuing securities transactions, the receipt of income and the payment of expenses, the Fund uses the prevailing exchange rate on the transaction date.

Net realized and unrealized gains and losses on foreign currency shown in the Fund's financial statements result from the sale of foreign currencies, from currency gains or losses realized between the trade and settlement dates of securities transactions, and from the difference between the amounts of dividends, interest and foreign withholding taxes recorded on the Fund's books and the U.S. dollar equivalent of the amounts actually received or paid.

When calculating realized and unrealized gains or losses on equity investments, the Fund does not separate the gain or loss attributable to changes in the foreign currency price of the security from the gain or loss attributable to the change in the U.S. dollar value of the foreign currency. Other foreign currency translations resulting in realized and unrealized gain or loss are disclosed separately.

**D. Estimates**

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the increases and decreases in net assets from operations during the reporting period. Actual results could differ from those estimates.

**E. Concentration of Market Risk**

The Fund primarily invests in securities of Swiss issuers. Such investments may carry certain risks not ordinarily associated with investments in securities of U.S. issuers. These risks include future political and economic developments, unfavorable movements in the U.S. dollar relative to the Swiss franc, and the possible imposition of exchange controls and changes in governmental law and restrictions. In addition, concentrations of investments in securities of issuers located in a specific region expose the Fund to the economic and government policies of that region and may increase risk compared to a fund whose investments are more diversified.

**Note 2 Capital Commitments**

As of September 30, 2014, the Fund maintains illiquid investments in two private equity limited partnerships. These investments appear in the Fund's Schedule of Investments. The Fund's capital commitments for these partnerships are shown in the table below:

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

Investments	Original Capital Commitment*	Unfunded Commitment*	Fair Value as of September 30, 2014
<b>Private Equity Limited Partnerships International (a)</b>			
Aravis Biotech II, Limited Partnership	\$ 3,401,361	\$ 409,524	\$ 2,836,870
Zurmont Madison Private Equity, Limited Partnership	14,652,015	380,380	14,374,878

\* The original capital commitment represents 3,250,000 and 14,000,000 Swiss francs for Aravis Biotech II, LP and Zurmont Madison Private Equity LP, respectively. The unfunded commitment represents 391,300 and 363,453 Swiss francs, respectively. The Swiss franc (CHF)/U.S. dollar exchange rate as of September 30, 2014 was used for conversion and equals 0.9555.

(a) This category consists of two private equity limited partnerships that invest primarily in ventures, biotechnology and in management buyout of industrial and consumer goods companies. There is no redemption right for the interests in these two limited partnerships. Instead, the nature of the investments in this category is that distributions are received through the realization of the underlying assets of the limited partnership.

**Item 2. Controls and Procedures.**

- (a) The registrant's principal executive officer and principal financial officer have concluded, based on their evaluation of the registrant's disclosure controls and procedures as of a date within 90 days of the filing date of this report on Form N-Q, that the design and operation of such procedures are effective to provide reasonable assurance that information required to be disclosed by the investment company on Form N-Q is recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms.
  
- (b) There have been no changes in the registrant's internal control over financial reporting during the period from July 1, 2014 through September 30, 2014 that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

**Item 3. Exhibits.**

Certifications pursuant to Rule 30a-2(a) under the Investment Company Act of 1940 (Exhibit filed herewith).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant):                      The Swiss Helvetia Fund, Inc.

By (Signature and Title)\*: /s/ Mark A. Hemenetz

Mark A. Hemenetz, Principal Executive Officer

Date: November 28, 2014

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By (Signature and Title)\*: /s/ Mark A. Hemenetz

Mark A. Hemenetz, Principal Executive Officer

Date: November 28, 2014

By (Signature and Title)\*: /s/ Alan M. Mandel

Alan M. Mandel, Treasurer and Principal Financial Officer

Date: November 28, 2014